Investors
Investor Information
Revolo Biotherapeutics is a privately held, venture-funded biotechnology firm engaged in the development of unique and revolutionary therapies. Looking to learn more? Don’t hesitate to contact us.
![](https://revolobio.com/wp-content/uploads/investors-hero.png)
Events
Upcoming Events
There are no upcoming events at this time.
Past Events
19
May
Poster – IRL201104, a Novel Immunomodulatory Peptide, Prevents Inflammatory Infiltration and Proinflammatory Cytokine Release in a New Model of ARDS Associated to Influenza Infection – Washinton, D.C.
20
Apr
April 20th 2023 – 8th Food Allergy Fund Summit
Corporate presentation – New York
27
Feb
February 27th 2023 – 2023 American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
Oral Presentation – IRL201104, A Novel Immunomodulatory Peptide, Shows A Long Lasting Reduction In Anaphylaxis Symptoms And Allergy Biomarkers In A Murine Model Of Food Allergy – San Antonio
Investors
![](https://revolobio.com/wp-content/uploads/investors_morningside_2x-3.png)
![24 Haymarket (UK)](https://revolobio.com/wp-content/uploads/investors_24haymarket_2x.png)
![Metellus AG (Switzerland)](https://revolobio.com/wp-content/uploads/investors_metellusag_2x.png)